Ranbaxy's "corrective" plan under FDA review

Is there light at the end of the importing tunnel for Ranbaxy Laboratories? The FDA says it's reviewing the Indian drugmaker's "corrective action" plan, filed in response to last fall's ban on 30 meds from two of the company's factories. The agency has also barred new generics from one of those two plants. The two bans cut deeply into Ranbaxy's revenues and sent its stock spiraling downward, at least until new CEO Abul Sobti said the company had submitted the plan, Bloomberg reports.

No word on just what the action plan includes. And the FDA hasn't said how long its negotiations with Ranbaxy might take. But the regulatory problems--and the underlying problems they exposed at the company--have taken a major toll, not only on the company itself, but on its new parent Daiichi Sankyo, which acquired a 64 percent stake last year. Daiichi put a firmer hand on Ranbaxy's tiller earlier this week, installing one of its own as chairman and replacing CEO Malvinder Singh with COO Sobti.

Meanwhile, Daiichi has revised its fiscal year results to restate the effect of Ranbaxy's slide on its own finances. New Japanese accounting guidelines allow the company to book a smaller loss on Ranbaxy stock, which changes Daiichi's net loss for the year ended in March to $2.26 billion from the $3.49 billion or so reported a couple weeks ago.

- read the Bloomberg story
- check out the Wall Street Journal piece

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.